BWP
GMAB icon

Baldwin Wealth Partners’s Genmab GMAB Stock Holding History

Baldwin Wealth Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,172
Closed -$272K – 553
2024
Q3 		$272K Buy
+11,172
New +$299K 0.02% 285

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Baldwin Wealth Partners's GMAB Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Genmab (GMAB) in Q4 2024, closing a stake of 11,172 shares — an estimated $272K sold.

Baldwin Wealth Partners first reported a position in GMAB in Q3 2024 and held it in 1 quarter. The position peaked at $272K in Q3 2024. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • Baldwin Wealth Partners reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • Baldwin Wealth Partners sold 11,172 Genmab shares in Q4 2024, an estimated $272K.
  • Baldwin Wealth Partners first reported a position in Genmab in Q3 2024 and held it in 1 quarter.
  • Baldwin Wealth Partners's Genmab position peaked at $272K in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.